Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation. Thoratec Ventricular Assist Device Principal Investigators
- PMID: 8167132
Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation. Thoratec Ventricular Assist Device Principal Investigators
Abstract
Approximately two-thirds of patients implanted with ventricular assist devices recover sufficiently to requalify for heart transplantation, and the other one-third die of complications that are often secondary to delayed ventricular assist device implantation and subsequent end-organ failure. To determine whether any preoperative predictors of survival exist, univariate statistics and multivariate stepwise logistic regression analysis were performed on pre-ventricular assist device demographics, hemodynamics, and blood chemistry in 186 patients receiving Thoratec ventricular assist devices (Thoratec Laboratories Corp., Berkeley, Calif.) while awaiting transplantation. The duration of circulatory support averaged 19.6 days (maximum, 226 days). One hundred thirty-seven patients (74%) received biventricular support, 47 received isolated left ventricular assist devices, and two received right ventricular assist devices. The average blood flow was 5.0 +/- 0.9 L/min. One hundred eighteen patients (63%) ultimately received heart transplants, of whom 96 patients were discharged. Age, gender, weight, and diagnosis were not related to survival, nor were preoperative cardiac index, pulmonary capillary wedge pressure, intraaortic balloon pumps, or cardiac arrests. Pre-ventricular assist device creatinine levels (p = 0.24) and total bilirubin levels (p = 0.09) were not significant, but blood urea nitrogen level (p = 0.02) and previous operations (p = 0.05) were related to survival, using univariate techniques. Patients with cardiac operations more than 30 days previously had the lowest survival-to-transplantation (39%) compared with patients with no previous operations (67%) or operations within the previous 30 days (61%). Blood urea nitrogen level was the only parameter found to be significant (p = 0.016) in a multivariate model.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Recovery of major organ function in patients awaiting heart transplantation with Thoratec ventricular assist devices. Thoratec Ventricular Assist Device Principal Investigators.J Heart Lung Transplant. 1994 Nov-Dec;13(6):1125-32. J Heart Lung Transplant. 1994. PMID: 7865520
-
Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes.J Thorac Cardiovasc Surg. 2010 May;139(5):1316-24. doi: 10.1016/j.jtcvs.2009.11.020. Epub 2010 Feb 4. J Thorac Cardiovasc Surg. 2010. PMID: 20132950
-
Seven years' experience with the Pierce-Donachy ventricular assist device.J Thorac Cardiovasc Surg. 1988 Dec;96(6):901-11. J Thorac Cardiovasc Surg. 1988. PMID: 3057290
-
Right ventricular assist devices and the surgical treatment of right ventricular failure.Cardiol Clin. 1992 Feb;10(1):185-92. Cardiol Clin. 1992. PMID: 1739958 Review.
-
[Mechanical circulatory support. 2: Ventricular assist systems].Zentralbl Chir. 1995;120(3):166-73. Zentralbl Chir. 1995. PMID: 7754717 Review. German.
Cited by
-
Percutaneous ventricular assist device placement during active cardiopulmonary resuscitation for severe refractory cardiogenic shock after acute myocardial infarction.Tex Heart Inst J. 2007;34(2):204-8. Tex Heart Inst J. 2007. PMID: 17622370 Free PMC article.
-
Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.Am J Cardiol. 2013 Nov 1;112(9):1484-8. doi: 10.1016/j.amjcard.2013.06.023. Epub 2013 Jul 25. Am J Cardiol. 2013. PMID: 23891248 Free PMC article.
-
The use of extracorporeal membrane oxygenation in patients with therapy refractory cardiogenic shock as a bridge to implantable left ventricular assist device and perioperative right heart support.J Artif Organs. 2009;12(3):160-5. doi: 10.1007/s10047-009-0464-5. Epub 2009 Sep 19. J Artif Organs. 2009. PMID: 19894089
-
Thoratec paracorporeal biventricular assist device therapy: the Freiburg experience.Eur J Cardiothorac Surg. 2012 Jan;41(1):207-12; discussion 212. doi: 10.1016/j.ejcts.2011.04.002. Eur J Cardiothorac Surg. 2012. PMID: 21592811 Free PMC article.
-
Derivation and validation of the bridge to transplantation with left ventricular assist device score for 1 year mortality after heart transplantation. The BTT-LVAD score.Int J Artif Organs. 2022 May;45(5):470-477. doi: 10.1177/03913988221082690. Epub 2022 Apr 1. Int J Artif Organs. 2022. PMID: 35365063 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Medical